Budget Impact Analysis of the Incorporation of Ibrutinib for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia in the Brazilian Private Health Care System
May 1, 2016, 00:00
10.1016/j.jval.2016.03.1551
https://www.valueinhealthjournal.com/article/S1098-3015(16)01619-3/fulltext
Title :
Budget Impact Analysis of the Incorporation of Ibrutinib for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia in the Brazilian Private Health Care System
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)01619-3&doi=10.1016/j.jval.2016.03.1551
First page :
A143
Section Title :
Cancer - Cost Studies
Open access? :
No
Section Order :
268